Bioventus (BVS) Stock Forecast, Price Target & Predictions
BVS Stock Forecast
Bioventus stock forecast is as follows: an average price target of $7.50 (represents a -32.86% downside from BVS’s last price of $11.17) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
BVS Price Target
The average price target for Bioventus (BVS) is $7.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $2.50. This represents a potential -32.86% downside from BVS's last price of $11.17.
BVS Analyst Ratings
According to 3 Wall Street analysts, Bioventus's rating consensus is 'Buy'. The analyst rating breakdown for BVS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bioventus Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 07, 2024 | Chase Knickerbocker | Craig-Hallum | $12.00 | $8.25 | 45.45% | 7.43% |
| May 07, 2024 | William Plovanic | Canaccord Genuity | $8.00 | $5.12 | 56.25% | -28.38% |
| Mar 13, 2024 | Alex Nowak | Craig-Hallum | $9.00 | $5.29 | 70.13% | -19.43% |
| Nov 30, 2022 | - | Goldman Sachs | $2.50 | $1.91 | 30.89% | -77.62% |
The latest Bioventus stock forecast, released on Aug 07, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $12.00, which represents a 45.45% increase from the stock price at the time of the forecast ($8.25), and a 7.43% increase from BVS last price ($11.17).
Bioventus Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $12.00 | $9.67 |
| Last Closing Price | $11.17 | $11.17 | $11.17 |
| Upside/Downside | -100.00% | 7.43% | -13.43% |
In the current month, the average price target of Bioventus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bioventus's last price of $11.17. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | Craig-Hallum | Buy | Buy | Hold |
| May 07, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Dec 07, 2023 | Canaccord Genuity | - | Buy | Upgrade |
| Nov 30, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
| Nov 22, 2022 | Craig-Hallum | - | Hold | Downgrade |
Bioventus's last stock rating was published by Craig-Hallum on Aug 07, 2024. The company gave BVS a "Buy" rating, the same as its previous rate.
Bioventus Financial Forecast
Bioventus Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $135.42M | - | $137.07M | $119.06M | $125.83M | $137.07M | $140.33M | $117.29M | $130.41M | $108.89M | $109.82M | $81.78M | $98.59M |
| Avg Forecast | $159.40M | $144.85M | $158.65M | $137.30M | $148.10M | $133.23M | $137.60M | $118.37M | $123.96M | $119.00M | $129.23M | $116.57M | $132.59M | $141.59M | $138.33M | $117.69M | $130.23M | $102.39M | $100.97M | $76.54M | $98.08M |
| High Forecast | $160.56M | $145.90M | $159.81M | $138.30M | $149.18M | $134.20M | $138.60M | $119.23M | $124.86M | $119.87M | $130.17M | $117.42M | $133.56M | $142.63M | $138.84M | $118.12M | $130.70M | $102.76M | $101.33M | $76.82M | $98.44M |
| Low Forecast | $158.53M | $144.06M | $157.78M | $136.55M | $147.29M | $132.50M | $136.85M | $117.72M | $123.28M | $118.35M | $128.53M | $115.93M | $131.86M | $140.82M | $137.95M | $117.37M | $129.87M | $102.11M | $100.69M | $76.33M | $97.81M |
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.09% | - | 1.06% | 1.02% | 0.95% | 0.97% | 1.01% | 1.00% | 1.00% | 1.06% | 1.09% | 1.07% | 1.01% |
Bioventus's average Quarter revenue forecast for Mar 24 based on 1 analysts is $118.37M, with a low forecast of $117.72M, and a high forecast of $119.23M. BVS's average Quarter revenue forecast represents a -12.59% decrease compared to the company's last Quarter revenue of $135.42M (Dec 23).
Bioventus EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $52.56M | - | $55.23M | $82.85M | $-4.29M | $35.58M | $11.64M | $-7.28M | $9.56M | $7.92M | $5.07M | $32.05M | $13.18M |
| Avg Forecast | $21.67M | $19.69M | $21.57M | $18.66M | $20.13M | $18.11M | $18.70M | $16.09M | $16.85M | $16.18M | $17.57M | $15.85M | $18.02M | $19.25M | $18.80M | $16.00M | $17.70M | $13.92M | $13.72M | $10.40M | $13.33M |
| High Forecast | $21.83M | $19.83M | $21.72M | $18.80M | $20.28M | $18.24M | $18.84M | $16.21M | $16.97M | $16.29M | $17.69M | $15.96M | $18.15M | $19.39M | $18.87M | $16.06M | $17.77M | $13.97M | $13.77M | $10.44M | $13.38M |
| Low Forecast | $21.55M | $19.58M | $21.45M | $18.56M | $20.02M | $18.01M | $18.60M | $16.00M | $16.76M | $16.09M | $17.47M | $15.76M | $17.92M | $19.14M | $18.75M | $15.95M | $17.65M | $13.88M | $13.69M | $10.38M | $13.30M |
| Surprise % | - | - | - | - | - | - | - | - | 3.12% | - | 3.14% | 5.23% | -0.24% | 1.85% | 0.62% | -0.46% | 0.54% | 0.57% | 0.37% | 3.08% | 0.99% |
1 analysts predict BVS's average Quarter EBITDA for Mar 24 to be $16.09M, with a high of $16.21M and a low of $16.00M. This is -69.39% lower than Bioventus's previous annual EBITDA (Dec 23) of $52.56M.
Bioventus Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-6.10M | - | $-3.68M | $-100.02M | $-44.87M | $3.17M | $-8.01M | $-14.81M | $-1.89M | $-1.07M | $-4.13M | $24.94M | $2.78M |
| Avg Forecast | $14.80M | $7.41M | $14.98M | $4.43M | $7.36M | $1.04M | $4.31M | $-4.27M | $1.23M | $-1.28M | $-213.50K | $-9.61M | $3.08M | $7.87M | $9.98M | $3.05M | $11.29M | $9.00M | $8.75M | $145.88M | $14.73M |
| High Forecast | $14.94M | $7.48M | $15.12M | $4.47M | $7.43M | $1.05M | $4.35M | $-4.24M | $1.24M | $-1.27M | $-211.98K | $-9.54M | $3.11M | $7.95M | $10.02M | $3.07M | $11.35M | $9.04M | $8.79M | $175.05M | $14.80M |
| Low Forecast | $14.70M | $7.36M | $14.88M | $4.40M | $7.31M | $1.03M | $4.28M | $-4.31M | $1.22M | $-1.29M | $-215.52K | $-9.70M | $3.05M | $7.82M | $9.94M | $3.04M | $11.25M | $8.97M | $8.72M | $116.70M | $14.68M |
| Surprise % | - | - | - | - | - | - | - | - | -4.97% | - | 17.24% | 10.41% | -14.59% | 0.40% | -0.80% | -4.85% | -0.17% | -0.12% | -0.47% | 0.17% | 0.19% |
Bioventus's average Quarter net income forecast for Dec 22 is $3.08M, with a range of $3.05M to $3.11M. BVS's average Quarter net income forecast represents a -3.10% decrease compared to the company's last Quarter net income of $3.17M (Sep 22).
Bioventus SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $78.36M | - | $74.84M | $80.86M | $77.67M | $84.33M | $89.62M | $86.12M | $80.88M | $69.64M | $69.05M | $34.69M | $61.97M |
| Avg Forecast | $95.32M | $86.62M | $94.87M | $82.11M | $88.56M | $79.67M | $82.29M | $70.78M | $74.13M | $71.16M | $77.28M | $69.71M | $79.29M | $84.67M | $82.72M | $70.38M | $77.88M | $61.23M | $60.38M | $45.77M | $58.65M |
| High Forecast | $96.02M | $87.25M | $95.56M | $82.70M | $89.21M | $80.25M | $82.88M | $71.30M | $74.67M | $71.68M | $77.85M | $70.22M | $79.87M | $85.29M | $83.03M | $70.64M | $78.16M | $61.45M | $60.60M | $45.94M | $58.87M |
| Low Forecast | $94.80M | $86.15M | $94.35M | $81.66M | $88.08M | $79.24M | $81.84M | $70.40M | $73.72M | $70.77M | $76.86M | $69.33M | $78.86M | $84.21M | $82.50M | $70.19M | $77.66M | $61.06M | $60.21M | $45.65M | $58.49M |
| Surprise % | - | - | - | - | - | - | - | - | 1.06% | - | 0.97% | 1.16% | 0.98% | 1.00% | 1.08% | 1.22% | 1.04% | 1.14% | 1.14% | 0.76% | 1.06% |
Bioventus's average Quarter SG&A projection for Mar 24 is $70.78M, based on 1 Wall Street analysts, with a range of $70.40M to $71.30M. The forecast indicates a -9.66% fall compared to BVS last annual SG&A of $78.36M (Dec 23).
Bioventus EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.10 | - | $-0.06 | $-1.61 | $-0.72 | $0.05 | $-0.13 | $-0.24 | $-0.03 | $-0.03 | $-0.10 | $0.60 | $0.07 |
| Avg Forecast | $0.23 | $0.12 | $0.23 | $0.07 | $0.11 | $0.02 | $0.07 | $-0.07 | $0.02 | $-0.02 | $-0.00 | $-0.15 | $0.05 | $0.12 | $0.16 | $0.05 | $0.18 | $0.14 | $0.14 | $0.28 | $0.23 |
| High Forecast | $0.23 | $0.12 | $0.24 | $0.07 | $0.12 | $0.02 | $0.07 | $-0.07 | $0.02 | $-0.02 | $-0.00 | $-0.15 | $0.05 | $0.12 | $0.16 | $0.05 | $0.18 | $0.14 | $0.14 | $0.28 | $0.23 |
| Low Forecast | $0.23 | $0.11 | $0.23 | $0.07 | $0.11 | $0.02 | $0.07 | $-0.07 | $0.02 | $-0.02 | $-0.00 | $-0.15 | $0.05 | $0.12 | $0.16 | $0.05 | $0.18 | $0.14 | $0.14 | $0.28 | $0.23 |
| Surprise % | - | - | - | - | - | - | - | - | -5.05% | - | 17.64% | 10.73% | -14.99% | 0.42% | -0.83% | -5.04% | -0.20% | -0.21% | -0.73% | 2.13% | 0.30% |
According to 0 Wall Street analysts, Bioventus's projected average Quarter EPS for Dec 22 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a -6.74% decrease compared to BVS previous annual EPS of $0.05 (Sep 22).
BVS Forecast FAQ
Is Bioventus a good buy?
Yes, according to 3 Wall Street analysts, Bioventus (BVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of BVS's total ratings.
What is BVS's price target?
Bioventus (BVS) average price target is $7.5 with a range of $2.5 to $12, implying a -32.86% from its last price of $11.17. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bioventus stock go up soon?
According to Wall Street analysts' prediction for BVS stock, the company can go down by -32.86% (from the last price of $11.17 to the average price target of $7.5), up by 7.43% based on the highest stock price target, and down by -77.62% based on the lowest stock price target.
Can Bioventus stock reach $20?
BVS's average twelve months analyst stock price target of $7.5 does not support the claim that Bioventus can reach $20 in the near future.
What are Bioventus's analysts' financial forecasts?
Bioventus's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $537.3M (high $541.21M, low $534.36M), average EBITDA is $73.04M (high $73.57M, low $72.64M), average net income is $8.44M (high $8.59M, low $8.31M), average SG&A $321.31M (high $323.65M, low $319.55M), and average EPS is $0.132 (high $0.134, low $0.13). BVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $600.2M (high $604.57M, low $596.91M), average EBITDA is $81.59M (high $82.18M, low $81.14M), average net income is $41.63M (high $42.02M, low $41.33M), average SG&A $358.92M (high $361.54M, low $356.96M), and average EPS is $0.65 (high $0.656, low $0.645).
Did the BVS's actual financial results beat the analysts' financial forecasts?
Based on Bioventus's last annual report (Dec 2023), the company's revenue was $100K, which missed the average analysts forecast of $488.76M by -99.98%. Apple's EBITDA was $38K, missing the average prediction of $66.44M by -99.94%. The company's net income was $0, missing the average estimation of $-9.877M by -100.00%. Apple's SG&A was $59.4K, missing the average forecast of $292.28M by -99.98%. Lastly, the company's EPS was $0, missing the average prediction of $-0.154 by -100.00%. In terms of the last quarterly report (Dec 2023), Bioventus's revenue was $135.42M, beating the average analysts' forecast of $123.96M by 9.25%. The company's EBITDA was $52.56M, beating the average prediction of $16.85M by 211.91%. Bioventus's net income was $-6.096M, missing the average estimation of $1.23M by -597.05%. The company's SG&A was $78.36M, beating the average forecast of $74.13M by 5.71%. Lastly, the company's EPS was $-0.0966, missing the average prediction of $0.0191 by -604.54%